PPIs

Proton pump inhibitors and pharmacogenetics

Also known as: Acid reflux medications, Stomach acid reducers

4 medications 4 brand products CYP2C19

Why pharmacogenetics matter for proton pump inhibitors

Proton pump inhibitors (PPIs) are among the most prescribed drugs globally, used for GERD, peptic ulcer disease, and Helicobacter pylori eradication. Most PPIs are metabolized predominantly by CYP2C19. Rapid and ultrarapid metabolizers clear PPIs faster and may need higher or more frequent doses to achieve acid suppression equivalent to a normal metabolizer.

CYP2C19 matters most clinically for H. pylori eradication, where treatment success correlates with time spent above a pH threshold. Rapid metabolizers on standard PPI doses can fall short of the required acid suppression, contributing to eradication failure.

Key gene in this class

CYP2C19

Cytochrome P450 2C19

CYP2C19 handles several SSRIs (citalopram, escitalopram, sertraline), proton pump inhibitors (omeprazole, esomeprazole), and the blood thinner clopidogrel. About 2 to 5 percent of people of European descent and 15 to …

Medications in this class with pharmacogenetic guidelines

Each link goes to the drug's full pharmacogenetics page with CPIC and FDA phenotype recommendations.

Dexlansoprazole CYP2C19 Lansoprazole CYP2C19 Omeprazole CYP2C19 Pantoprazole CYP2C19

Brand products in the PPIs class

Combined products and brand names for the medications above. Each links to a pharmacogenetic breakdown.

Which ppis is right for your genetics?

This page covers the pharmacogenetics of proton pump inhibitors in general. A Gene2Rx report tells you how your personal genotype interacts with every drug on this page.

Get your report Look up a medication

Informational only, not medical advice. Pharmacogenetic guidelines describe population-level patterns that inform prescribing decisions. Never start, stop, or change a medication without talking to your prescribing clinician.